Adenomyosis
Conditions
Interventions
Drug group (Second part of the study):Gonadotropin-releasing hormone agonists ( GnRH-a)
HIFU group (Second part of the study):Gonadotropin-releasing hormone agonists ( GnRH-a)+High-intensity Focused ultrasound therapy (HIFU)
Surgery group (Third part of the study):Adenomyosis lesion resection +Gonadotropin-releasing hormone agonists ( GnRH-a)+Dinoprogesterone
HIFU group (Third part of the study):High-intensity Focused ultrasound therapy (HIFU)+Gonadotropin-releasing hormone agonists ( GnRH-a)+Dinoprogesterone
Drug group (Third part of the study):Gonadotropin-releasing hormone agonists ( GnRH-a)+Dinoprogesterone
Infertility group (First part of the study)(Total sample size: 456 cases, with infertility):Observational study, without intervention
Control group (First part of the study)(Total sample size: 456 cases, without infertility):Observational study, without intervention
Sponsors
The Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
Female
Age
25 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. First part of the study: ( 1 ) 30~45 years old ; ( 2 ) Ultrasound diagnosis of adenomyosis ; ( 3 ) Symptomatic patients. 2. Second part of the study: ( 1 ) 25~40 years old ; ( 2 ) Ultrasound and MRI diagnosis of adenomyosis ; ( 3 ) Symptomatic patients; (4) Uterine volume = the size of a 12-week pregnancy; (5) Plan for pregnancy. 3. Third part of the study: ( 1 ) 25~40 years old ; ( 2 ) Ultrasound and MRI diagnosis of adenomyosis ; ( 3 ) Symptomatic patients; (4) The uterine volume is greater than the size of a 12-week pregnancy but less than that of a 20-week pregnancy; (5) Have fertility demand, but have no pregnancy plans in the past two years.
Exclusion criteria
Exclusion criteria: 1. First part of the study: (1)Combined with female reproductive system precancerous lesions or malignant tumors ; (2) In the infertility group, patients were excluded from organic changes in the fallopian tubes, ovulation disorders and abnormal male semen ; (3)Combined with uterine leiomyoma, pelvic endometriosis, endometrial polyps or endometrial hyperplasia ; 2. Second part of the study: (1) combined with precancerous lesions or malignant tumors of the female reproductive system; (2) Infertile patients with organic changes of fallopian tubes, ovulation disorders and abnormal male semen. (3) patients unwilling to participate in the study; (4) patients with difficulty in follow-up; (5) complicated with uterine leiomyoma; (6) There were contraindications to pelvic enhanced MRI; (7) Patients with contraindications to HIFU treatment (not enrolled in HIFU group). 3. Third part of the study: (1) Has contraindications for oral denogestrel; (2) The remaining exclusion criterias are the same as those in the second part of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adenomyosis-related symptom scale;Ultrasound morphologies of uterine ;Magnetic resonance imagings of uterine ;Pregnancy outcomes; | — |
Countries
China
Contacts
Public ContactYuan Yuan
The Affiliated Hospital of Southwest Medical University
Outcome results
None listed